Sarcopenia
Conditions
Interventions
Control group:The control group will receive standard health education and usual care without structured exercise intervention. At baseline, participants will attend a health lecture on balanced diet,
Brisk Walking Group:Participants will undergo a 12-week brisk walking program, performed 3 times per week for approximately 40 minutes per session (5 min warm-up, 30 min brisk walking, 5 min cool-down
Combined Group:Participants will engage in a 12-week combined program, performed 3 times per week, each session lasting about 60 minutes: 5 min warm-up, 30 min bris
Sponsors
Shandong Normal University
Eligibility
Sex/Gender
Male
Age
60 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Sex & Age: Male, 60–70 years (inclusive). 2. Sarcopenia diagnosis: Meets AWGS 2019/2022 criteria 3. Medical clearance: Deemed suitable by a physician for moderate-intensity aerobic training and low-to-moderate-intensity resistance training; resting ECG and basic physical examination reveal no exercise contraindications. 4. Functional capacity & mobility: Able to ambulate independently for >= 6 minutes. 5. Communication & adherence: Able to understand and follow training and assessment instructions; provides written informed consent; expected to complete a 12-week intervention (3 sessions/week) and three assessments (T0/T1/T2). 6. Residence/accessibility: Home–center distance and scheduling allow on-time visits to complete the intervention and assessments.
Exclusion criteria
Exclusion criteria: 1. Cardiovascular & Metabolic Contraindications/High Risk Occurred within the past 6 months: acute myocardial infarction; unstable angina; documented severe arrhythmia requiring urgent management; post-resuscitation state; or uncontrolled heart failure (NYHA class III–IV). Uncontrolled hypertension: systolic BP = 160 mmHg or diastolic BP = 100 mmHg at rest on repeated measurements; or resting heart rate > 100 bpm. Uncontrolled diabetes (with prominent symptoms or acute complications), or recent recurrent severe hypoglycemia; HbA1c > 9% with unstable complications. Severe anemia (e.g., Hb < 90 g/L), or other serious hematologic/endocrine diseases affecting exercise safety. 2. Respiratory, Neurologic, and Musculoskeletal Limitations Severe COPD/asthma with an acute exacerbation in the past 4 weeks, or marked hypoxemia at rest/with minimal activity. Neurologic disorders causing significant motor impairment or instability (e.g., new stroke within 6 months with severe residual deficits; advanced progressive Parkinson’s disease; uncontrolled epilepsy). Acute or unhealed musculoskeletal injury; surgery to relevant regions within the past <3 months; severe osteoarthritis (Kellgren–Lawrence grade IV) causing severe pain or instability during walking/squatting; severe osteoporosis with a recent fragility fracture. 3. Cognitive and Mental Status Marked cognitive impairment affecting adherence (e.g., MMSE < 24 or MoCA < 20), or acute psychiatric disorders; severe depression/anxiety that is not stabilized. 4. Measurement-Related and Intervention-Interfering Factors If using BIA to assess muscle mass: exclude individuals with implanted cardiac pacemakers/defibrillators (BIA contraindication). If using DXA primarily: unable to lie supine/cooperate, or extensive metal implants causing severe measurement artifacts that cannot be corrected. Regular participation in moderate-to-vigorous resistance training or a structured fitness program = 2 times/week in the past 3 months (may dilute intervention effects). Medication interference: initiation or adjustment within the past 3 months of drugs likely to significantly affect muscle metabolism (e.g., anabolic agents/testosterone replacement, high-dose glucocorticoids) or newly started medications affecting exercise tolerance (as determined by the study physician). Concurrent interventions: currently participating in clinical trials or behavioral interventions that conflict with this study’s objectives. 5. Other General Exclusions Inability to complete follow-up or plans to relocate within 3 months; poor adherence or high likelihood of dropout. Any other condition deemed unsuitable for study participation by the study physician (participant safety has the highest priority).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Short Physical Performance Battery; | — |
Secondary
| Measure | Time frame |
|---|---|
| Digit Symbol Substitution Test;Sit-and-Reach Test;Cross-Body Reach Test;Satisfaction with Life Scale;Sleep Quality Index;Lubben Social Network Scale-6;Handgrip strength;Gait speed; | — |
Countries
China
Contacts
Public ContactYang Xiangkun
Shandong Normal University
Outcome results
None listed